GlassScriptPhysician profile
Neil Anthony Persaud
NPI 1356428700
$718.10
in general payments reported to CMS, 2019-2025
10 companies · $33.17 in 2025
The $33.17 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $74.91 · 2021: $42.47 · 2022: $233 · 2023: $147 · 2024: $15.23 · 2025: $33.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $277.76 | 2022-2024 | Nucala |
| Stryker Corporation | $142.70 | 2020-2022 | |
| Acclarent, INC | $79.47 | 2020-2023 | Acclarent Balloon Inflation Device |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $73.85 | 2019 | |
| Aerin Medical INC. | $41.35 | 2019-2020 | |
| Kaleo, INC. | $33.67 | 2019 | |
| Intersect Ent, INC. | $25.97 | 2019 | |
| Amgen INC. | $17.13 | 2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $16.04 | 2025 | Tezspire |
| Amniox Medical, INC. | $10.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Persaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.